Organigram Holdings Inc. (TSX-V: OGI; OTCQX: OGRMF) today announced the resignation of the company’s chief medical member from the board of directors. Effective immediately, Dr. Kenneth Mitton has stepped down from the role he held since 2014.
Before joining the Organigram board, Dr. Mitton spent three decades as a practicing family physician and used that experience to assist the company in navigating medical cannabis regulations.
Organigram’s Chief Executive Officer Greg Engel issued this brief statement about the resignation:
This is the second management structure shakeup in recent months, with Organigram recruiting Helen Martin as Corporate Secretary in early March. Martin moved into the role after briefly serving as the company’s Vice President of Strategic Initiatives and Legal Affairs.
In addition to the board and upper management changes, Organigram today announced the official launch of a new cross platform mobile app for medical patients. Greg Engel commented on the launch:
Engel further stated his hope that the app’s launch will reassure medical patients that they remain a priority after recreational adult usage became legalized across Canada last year. That issue has been a sticking point for advocacy groups, as low supply and high demand have impacted patients particularly hard since licensed producers began selling to the adult recreational market.
Now available for iOS and Android devices, the app allows customers to place orders for cannabis, view previous order history information, manage patient data, and chat with representatives about their care.
In addition to the app for medical customers, Organigram recently signed a letter of intent with the Société québécoise du cannabis for recreational sales. Once fully approved, Organigram will offer pre-rolled products and a variety of cannabis oils to Quebec consumers.
Following a previously announced supply agreement with British Columbia, that move officially cements the company’s foothold in the recreational market across all 10 provinces.
The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Grizzle hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.